Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer
Clinical Validation of a Urine-based Assay With Genomic and Epigenomic Markers for Predicting Recurrence During Surveillance for Non-muscle Invasive Bladder Cancer
Sponsor: Genomic Health®, Inc.
This observational or N/A phase trial investigates Non-muscle Invasive Bladder Cancer and is currently completed. Genomic Health®, Inc. leads this study, which shows 12 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Dec 2021 — Jul 2024 [monthly]
Completed
-
Apr 2021 — Dec 2021 [monthly]
Completed
Status: Unknown Status → Completed
-
Jan 2021 — Apr 2021 [monthly]
Unknown Status
▶ Show 7 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status
-
Dec 2018 — Nov 2020 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jun 2018 — Dec 2018 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genomic Health®, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .